I’m on the Surgeon’s Record
If you want to hear a little about Commons Clinic from Benjamin Schwartz, MD but rather more from me about who knows what, it’s on The Surgeon’s Record podcast — Matthew Holt
Read More
Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO market’s return to normal levels. The post Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More appeared first on…
An Arm and a Leg: A Listener Fighting the Good Fight
Joey Ballard is an internal medicine resident at the University of Illinois-Chicago. He wrote to “An Arm and a Leg” about a resolution the American Medical Association recently adopted calling on hospitals to do more to make sure patients who qualify for charity care get it. And that legislators and regulators make sure that’s happening….
Oct. 1 Virtual Event: What the 2024 Election Could Mean for Health Coverage, Affordability, and the Budget
As the 2024 presidential election draws near, there are sharp differences in former President Trump’s and Vice President Harris’ records on health coverage and spending, including the Affordable Care Act, Medicaid, prescription drugs, and more. At Noon ET on Tuesday, October 1, Larry Levitt, KFF’s executive vice president for health policy, will moderate a 45-minute…More
BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal
Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema. The post BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal appeared first on MedCity News.
Without Federal Action, States Wrestle With Kratom Regulation
HELENA, Mont. — Montana lawmakers are grappling with how — if at all — the state should rein in kratom, an unregulated plant-derived substance with addictive properties sold mainly as a mood and energy booster at gas stations, vape shops, and elsewhere. Kratom, which originates from the leaves of a tree native to Southeast Asia,…
Avandra Imaging Emerges from Stealth to Solve a Last-Mile Problem in Medical Research
Avandra Imaging, a federated network for de-identified imaging data, emerged from stealth at HLTH — as well as announced a partnership with Datavant. The post Avandra Imaging Emerges from Stealth to Solve a Last-Mile Problem in Medical Research appeared first on MedCity News.
Watching Where and How You’re Walking
By MIKE MAGEE In a speech to the American Philosophical Society in January, 1946, J. Robert Oppenheimer said, “We have made a thing …that has altered abruptly and profoundly the nature of the world…We have raised again the question of whether science is good for man, of whether it is good to learn about the…
How does hospital participation in a Medicare Advantage preferred network impact commercial reimbursement?
How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. How would MA network participation impact commercial rates? Marr et al. (2025) offers some hypotheses: On the one hand,…
Growth Without Compromise: Building The Future of Medicines Sustainably
Through intentional design, renewable energy investments and a deep commitment to innovation and efficiency, we can redefine what responsible growth looks like. The post Growth Without Compromise: Building The Future of Medicines Sustainably appeared first on MedCity News.